To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride
plus niacin would produce significant change in coronary, carotid, and femoral artery
atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to
determine possible correlations between lesion changes and plasma lipid and lipoprotein
cholesterol levels and to explore interrelationships of atherosclerosis change in femoral,
coronary, and carotid arteries.